ABEO Abeona Therapeutics Inc.

Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan

Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan
EN
06/10/2020

Underlying

ABEOAbeona Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abeona Therapeutics Inc.

 PRESS RELEASE
Free
ABEO Abeona Therapeu...

Abeona Therapeutics® Announces Date of Third Quarter Financial Results...

Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation CLEVELAND, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Wednesday, November 12, 2025 at 8:30 a.m. ET to discuss its third quarter 2025 financial results and corporate progress. The conference call will be available via phone and webcast. To access the call, dial 877-545-0523 (U.S. toll-free) or 973-528-0016 (international) and Entry Code: 922481 five minutes prior to the start of the call. A li...

November 7, 2025 1 EN
 PRESS RELEASE
Free
ABEO Abeona Therapeu...

Abeona Therapeutics® Announces New Employee Inducement Grants Under Na...

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CLEVELAND, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On October 31, 2025, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to eleven individuals hired by Abeona, which equity awards relate to, ...

November 3, 2025 1 EN
 PRESS RELEASE
Free
ABEO Abeona Therapeu...

Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (pradema...

Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel) CLEVELAND, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced that the Centers for Medicare and Medicaid Services (CMS) has established a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets, the Company’s autologous gene therapy for the treatment of wounds in adult and pediatric ...

October 30, 2025 1 EN
 PRESS RELEASE
Free
ABEO Abeona Therapeu...

Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Seni...

Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs CLEVELAND, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the appointment of James A. Gow, MD, MBA, MS, MHCM, as the Senior Vice President, Head of Clinical Development & Medical Affairs, effective immediately. "We are thrilled to welcome Dr. Gow to our executive team," said Vish Seshadri, Chief Executive Offic...

October 20, 2025 1 EN
 PRESS RELEASE
Free
ABEO Abeona Therapeu...

Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retin...

Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program RDEA Pilot Program provides sponsors enhanced communication and collaboration with FDA to accelerate development of rare disease therapies CLEVELAND, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced that its ABO-503 gene therapy for X-linked retinoschisis (XLRS) has been selected to part...

October 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch